Research graph
References from Oncolytic virus–mediated GPC3 delivery overcomes antigen heterogeneity in hepatocellular carcinoma and enhances GPC3-directed immunotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · 2024 · External reference
Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States
10.1111/apt.12450 · 2013 · External reference
Trends in hepatocellular carcinoma mortality rates in the US and projections through 2040
10.1001/jamanetworkopen.2024.45525 · 2024 · External reference
Systemic therapy and sequencing options in advanced hepatocellular carcinoma: A systematic review and network meta-analysis
10.1001/jamaoncol.2020.4930 · 2020 · External reference
Precision treatment in advanced hepatocellular carcinoma
10.1016/j.ccell.2024.01.007 · 2024 · External reference
Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals
10.1186/s13045-025-01704-3 · 2025 · External reference
Advances in CAR-T cell therapy for hematologic and solid Malignancies: latest updates from 2024 ESMO Congress
10.1186/s13045-024-01639-1 · 2024 · External reference
Bispecific T cell engagers: an emerging therapy for management of hematologic Malignancies
10.1186/s13045-021-01084-4 · 2021 · External reference
Exploring treatment options in cancer: Tumor treatment strategies
10.1038/s41392-024-01856-7 · 2024 · External reference
Monoclonal antibody therapies for hematological Malignancies: Not just lineage-specific targets
10.3389/fimmu.2017.01936 · 2017 · External reference
FDA approval: blinatumomab
10.1158/1078-0432.ccr-15-0612 · 2015 · External reference
Overview of approved CAR-T products and utility in clinical practice
10.46989/001c.124277 · 2024 · External reference
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
10.1038/s41571-025-00992-5 · 2025 · External reference
Glypican-3: A new target for diagnosis and treatment of hepatocellular carcinoma
10.7150/jca.39972 · 2020 · External reference
Glypican-3: A novel and promising target for the treatment of hepatocellular carcinoma
10.3389/fonc.2022.824208 · 2022 · External reference
Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy
10.1080/14728222.2024.2416975 · 2024 · External reference
Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma
10.1016/j.anndiagpath.2010.10.004 · 2011 · External reference
Evaluation of glypican-3 in patients with hepatocellular carcinoma
10.3892/mco.2024.2796 · 2025 · External reference
CAR-T cells and BiTEs in solid tumors: challenges and perspectives
10.1186/s13045-021-01067-5 · 2021 · External reference
Bispecific T-cell engagers for cancer immunotherapy
10.1038/icb.2014.93 · 2015 · External reference
A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release
10.1038/s41421-018-0066-6 · 2018 · External reference
A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma
10.1007/s00432-022-04132-9 · 2023 · External reference
Viruses and interferon: a fight for supremacy
10.1038/nri888 · 2002 · External reference
Oncolytic viruses: a new class of immunotherapy drugs
10.1038/nrd4663 · 2016 · External reference
Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose
10.1186/s12967-018-1483-x · 2018 · External reference
TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
10.1093/nar/gkv1507 · 2016 · External reference
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
10.1186/s13059-014-0550-8 · 2014 · External reference
Antibody dependent cell-mediated cytotoxicity selection pressure induces diverse mechanisms of resistance
10.1080/15384047.2023.2269637 · 2023 · External reference
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma
10.1016/j.jhep.2016.04.004 · 2016 · External reference
Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression
10.1007/s00262-025-04039-7 · 2025 · External reference
Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors
10.1126/scitranslmed.aaz1863 · 2020 · External reference
Mesothelin targeted cancer immunotherapy
10.1016/j.ejca.2007.08.028 · 2008 · External reference
A Frizzled-Like Cysteine-Rich Domain in Glypican-3 mediates Wnt binding and regulates hepatocellular carcinoma tumor growth in mice
10.1002/hep.30646 · 2019 · External reference
Vaccinia virus arrests and shifts the cell cycle
10.3390/v14020431 · 2022 · External reference
Trends in hepatocellular carcinoma mortality rates in the US and projections through 2040
10.1001/jamanetworkopen.2024.45525 · ExternalCitation · doi-reference
Systemic therapy and sequencing options in advanced hepatocellular carcinoma: A systematic review and network meta-analysis
10.1001/jamaoncol.2020.4930 · ExternalCitation · doi-reference
A Frizzled-Like Cysteine-Rich Domain in Glypican-3 mediates Wnt binding and regulates hepatocellular carcinoma tumor growth in mice
10.1002/hep.30646 · ExternalCitation · doi-reference
Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression
10.1007/s00262-025-04039-7 · ExternalCitation · doi-reference
A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma
10.1007/s00432-022-04132-9 · ExternalCitation · doi-reference
Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma
10.1016/j.anndiagpath.2010.10.004 · ExternalCitation · doi-reference
Precision treatment in advanced hepatocellular carcinoma
10.1016/j.ccell.2024.01.007 · ExternalCitation · doi-reference
Mesothelin targeted cancer immunotherapy
10.1016/j.ejca.2007.08.028 · ExternalCitation · doi-reference
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma
10.1016/j.jhep.2016.04.004 · ExternalCitation · doi-reference
Bispecific T-cell engagers for cancer immunotherapy
10.1038/icb.2014.93 · ExternalCitation · doi-reference
Oncolytic viruses: a new class of immunotherapy drugs
10.1038/nrd4663 · ExternalCitation · doi-reference
Viruses and interferon: a fight for supremacy
10.1038/nri888 · ExternalCitation · doi-reference
Exploring treatment options in cancer: Tumor treatment strategies
10.1038/s41392-024-01856-7 · ExternalCitation · doi-reference
A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release
10.1038/s41421-018-0066-6 · ExternalCitation · doi-reference
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
10.1038/s41571-025-00992-5 · ExternalCitation · doi-reference
Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy
10.1080/14728222.2024.2416975 · ExternalCitation · doi-reference
Antibody dependent cell-mediated cytotoxicity selection pressure induces diverse mechanisms of resistance
10.1080/15384047.2023.2269637 · ExternalCitation · doi-reference
TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
10.1093/nar/gkv1507 · ExternalCitation · doi-reference
Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States
10.1111/apt.12450 · ExternalCitation · doi-reference
Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors
10.1126/scitranslmed.aaz1863 · ExternalCitation · doi-reference
FDA approval: blinatumomab
10.1158/1078-0432.ccr-15-0612 · ExternalCitation · doi-reference
Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose
10.1186/s12967-018-1483-x · ExternalCitation · doi-reference
CAR-T cells and BiTEs in solid tumors: challenges and perspectives
10.1186/s13045-021-01067-5 · ExternalCitation · doi-reference
Bispecific T cell engagers: an emerging therapy for management of hematologic Malignancies
10.1186/s13045-021-01084-4 · ExternalCitation · doi-reference
Advances in CAR-T cell therapy for hematologic and solid Malignancies: latest updates from 2024 ESMO Congress
10.1186/s13045-024-01639-1 · ExternalCitation · doi-reference
Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals
10.1186/s13045-025-01704-3 · ExternalCitation · doi-reference
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
10.1186/s13059-014-0550-8 · ExternalCitation · doi-reference
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · ExternalCitation · doi-reference
Monoclonal antibody therapies for hematological Malignancies: Not just lineage-specific targets
10.3389/fimmu.2017.01936 · ExternalCitation · doi-reference
Glypican-3: A novel and promising target for the treatment of hepatocellular carcinoma
10.3389/fonc.2022.824208 · ExternalCitation · doi-reference
Vaccinia virus arrests and shifts the cell cycle
10.3390/v14020431 · ExternalCitation · doi-reference
Evaluation of glypican-3 in patients with hepatocellular carcinoma
10.3892/mco.2024.2796 · ExternalCitation · doi-reference
Overview of approved CAR-T products and utility in clinical practice
10.46989/001c.124277 · ExternalCitation · doi-reference
Glypican-3: A new target for diagnosis and treatment of hepatocellular carcinoma
10.7150/jca.39972 · ExternalCitation · doi-reference
